🇺🇸 FDA
Patent

US 12331132

Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses

granted A61PA61P35/00

Quick answer

US patent 12331132 (Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses) held by Inhibrx Biosciences, Inc. expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inhibrx Biosciences, Inc.
Grant date
Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61P, A61P35/00